Schizophrenia Research
Volume 89, Issue 1 , Pages 91-100 , January 2007

Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

Received 11 July 2006 ,Revised 13 August 2006 ,Accepted 16 August 2006.

References 

  1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999;156(11):1686–1696Nov
  2. American Diabetes Association , American Psychiatric Association , American Association of Clinical Endocrinologists , et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry. 2004;65:267–272
  3. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J. Clin. Psychiatry. 2005;66(1):63–72
  4. Aziz S, Hsiang YH. Comparative study of home blood glucose monitoring devices: Visidex, Chemstrip bG, Glucometer, and Accu-Chek bG. Diabetes Care. 1983;6:529–532
  5. Bovet P, Faeh D, Gabriel A, Tappy L. The prediction of insulin resistance with serum triglyceride and high-density lipoprotein cholesterol levels in an East African population. Arch. Intern. Med. 2006;166(11):1236–1237(Jun 12)
  6. Bray GA. Medical consequences of obesity. J. Clin. Endocrinol. Metab. 2004;89:2583–2589
  7. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry. 2000;177:212–217(Sep)
  8. Brunot A, Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F, et al. Pharmaco-epidemiological study on antipsychotic drug prescription in French psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale. 2002;28(2):129–138
  9. Chee YK, Ungvari GS, Kin CH, et al. A survey of antipsychotic treatment for schizophrenia in Hong Kong. Chin. Med. J. 1997;110:792–796
  10. Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr. Serv. 2004;55(9):1006–1013
  11. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr. Bull. 2002;28(1):75–84
  12. Correll CU, Kane JM. Is there a rationale for antipsychotic polypharmacy in schizophrenia?. In:  Fleischhacker WW,  Hummer M editor. Schizophrene Stoerungen — State of the Art III. Innsbruck: Verlag Integrative Psychiatrie; 2004;p. 95–112
  13. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J. Clin. Psychiatry. 2006;67(4):575–583(Apr)
  14. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J. Clin. Psychiatry. 1999;60(Suppl 10):20–30.9
  15. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol (adult treatment part III). JAMA. 2001;285:2486–2497
  16. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005;5(1):26;(May 27)
  17. Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lepine JP, Begaud B. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br. J. Clin. Pharmacol. 2000;49(1):80–86
  18. Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur. Psychiatr. 2000;15(3):220–226
  19. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J. Clin. Psychiatry. 2004;65(10):1377–1388(Oct)
  20. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 2005;80(1):45–53(Dec 1)
  21. Grundy SM. Obesity, metabolic syndrome and cardiovascular disease. J. Clin. Endocrinol. Metab. 2004;89:2595–2600
  22. Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr. Scand. 2006;113(2):142–147(Feb)
  23. Hida H, Faber M, Alberto-Gondouin MC, Jalaguier E. Analysis of prescriptions for psychotropic drugs in a psychiatric hospital. Therapie. 1997;52(6):573–578
  24. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N. Engl. J. Med. 2006;354(5):472–482
  25. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol. Drug Saf. 2003;12(1):41–48(Jan–Feb)
  26. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry. 2005;162(1):130–136(Jan)
  27. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br. J. Psychiatry. 2006;188:122–127(Feb)
  28. Keks NA, Altson K, Hope J, Krapivensky N, Culhane C, Tanaghow A, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust. N. Z. J. Psychiatry. 1999;33(6):896–901
  29. Kreyenbuhl, J., Valenstein, M., McCarthy, J.F., Ganoczy, D., Blow, F.C., in press. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr. Res. 84 (1), 90–99. (Electronic publication 2006 May 2).
  30. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry. 2004;161(2 Suppl):1–56
  31. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 2003;61(2–3):123–136(Jun 1)
  32. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005;80(1):19–32(Dec 1)
  33. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am. J. Cardiol. 2005;96(3):399–404(Aug 1)
  34. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry. 2004;65(Suppl 18):47–56
  35. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J. Clin. Psychiatry. 2004;5(4):500–508(Apr)
  36. Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J. Clin. Psychiatry. 2004;65(11):1491–1498(Nov)
  37. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93
  38. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res. 2000;45(1–2):21–28(Sep 29)
  39. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can. J. Psychiatry. 2001;46(4):334–339
  40. Reinstein AU, Sirotovskara LA, Jones LE, Mohan S, Chasanov MA. Effects of clozapine–quetiapine combination therapy on weight and glycaemic control. Clin. Drug Investig. 1999;19:99–104
  41. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br. J. Psychiatry. 1997;171:569–573
  42. Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br. J. Clin. Pharmacol. 2004;58(2):178–183(Aug, Erratum in: Br. J. Clin. Pharmacol. 2004 Nov; 58 (5): 564)
  43. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 2004;161(10):1837–1847(Oct)
  44. Stahl SM. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?. Int. J. Neuropsychopharmacol. 2004;7(2):113–116(Jun)
  45. Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am. J. Psychiatry. 2005;162(6):1217–1221(Jun)
  46. Sumner AE, Finley KB, Genovese DJ, Criqui MH, Boston RC. Fasting triglyceride and the triglyceride–HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch. Intern. Med. 2005;165(12):1395–1400(Jun 27)
  47. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, et al. Texas Consensus Conference Panel on medication treatment of bipolar disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry. 2005;66(7):870–886(Jul)
  48. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr. Serv. 2003;54(1):55–59
  49. Taylor D, Holmes R, Hilton T, Paton C. Evaluating and improving the quality of risperidone prescribing. Psychol. Bull. 1997;22:680–683
  50. Taylor D, Young C, Esop R, Paton C, Walwyn R. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br. J. Psychiatry. 2004;185:152–156(Aug)
  51. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br. J. Psychiatry. 1998;173:325–329
  52. Weiden PJ, Casey DE. “Polypharmacy”: combining antipsychotic medications in the treatment of schizophrenia. J. Pract. Psychiatry Behav. Health. 1999;5:229–233
  53. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J. Clin. Psychopharmacol. 2003;23(6):595–600(Dec)
  54. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration–New York metropolitan region. Schizophr. Bull. 2002;28(1):31–42
  55. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J. Clin. Psychiatry. 2002;63(10):856–865(Oct)

☆ Grant support: The Zucker Hillside Hospital Mental Advanced Center for Intervention and Services Research for the Study of Schizophrenia (MH074543-01) from the National Institute of Mental Health, Bethesda, Md.

PII: S0920-9964(06)00364-1

doi: 10.1016/j.schres.2006.08.017

Schizophrenia Research
Volume 89, Issue 1 , Pages 91-100 , January 2007

Article Tools

* Image Usage & Resolution